| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 30 Apr 2026 | 9 Apr 2026 |
| Laurus Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/04/2026 inter alia to consider and approve the Audited Financial Results For The Quarter And Year Ended March 31 2026 And Payment Of 2Nd Interim Dividend For FY 2025-26. Please see annexed Please see enclosed annexure (As Per BSE Announcement Dated on:30.04.2026) | ||
| Board Meeting | 12 Mar 2026 | 12 Mar 2026 |
| Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Appointment of Statutory Auditors of the Company | ||
| Board Meeting | 23 Jan 2026 | 9 Jan 2026 |
| Laurus Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/01/2026 inter alia to consider and approve the un-audited financial results of the Company for the quarter and nine months ended December 31 2025 Please see enclosed annexure. (As Per BSE Announcement Dated On : 22.01.2026) Please see annexed enclosure (As Per BSE Announcement Dated On : 23.01.2026) | ||
| Board Meeting | 23 Oct 2025 | 9 Oct 2025 |
| Laurus Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/10/2025 inter alia to consider and approve The Un-Audited Financial Results Of The Company For The Quarter And Half Year Ended September 30 2025 And The Proposal For Payment Of Interim Dividend For FY 2025-26. Outcome of the Board Meeting - October 23, 2025 (As per BSE Announcement dated on: 23.10.2025) | ||
| Board Meeting | 25 Jul 2025 | 9 Jul 2025 |
| Quarterly Results Please see attached Please see annexed Please see annexed (As Per BSE Announcement Dated on :25.07.2025) | ||
| Board Meeting | 15 May 2025 | 15 May 2025 |
| Please see annexed enclosure. | ||
Finished Dosage Formulations (FDF) business also saw a 27% growth, while the Generics business saw moderate growth of 5%
The said transaction falls under related party transactions. However, the same is being carried at arm’s length price.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
